Ranjit Kapadia

Analysts at Motilal Oswal believe that Lupin, Ranbaxy, Cadila Healthcare, GSK Pharma, Torrent Pharma and Alembic Pharma will report stronger overall operational performance during this quarter.

Sell Ranbaxy; target Rs 270: Ranjit Kapadia

Ranjit Kapadia, pharma analyst of Centrum Broking suggests selling Ranbaxy Laboratories with a target Rs 270.

How experts are reading Dr Reddy's Laboratories Q3 results

Q3 earnings have been broadly in line with our expectation. We were expecting good traction in bot Russia and America as they have been key drivers for the company for a pretty long time, Sarabjit Kaur Nangra of Angel Broking said.

Except Japan, Lupin saw good growth in all mkts: Centrum

Ranjit Kapadia, Senior VP - Pharma - Centrum Broking says the firm‘s numbers are very good on the top-line and margins front.

Time Technoplast has target of Rs 75: Kapadia

Time Technoplast has target of Rs 75 over the period of one year, says Ranjit Kapadia, HDFC Securities.

Bilcare has target of Rs 808: Kapadia

Bilcare has target of Rs 808, says Ranjit Kapadia, HDFC Securities.

Kapadia positive on Biocon

Ranjit Kapadia, Vice President-Institutional Research, HDFC Securities is positive on Biocon.

Aurobindo Pharma has target of Rs 1626: Kapadia

Aurobindo Pharma has target of Rs 1626, says Ranjit Kapadia, Vice President-Institutional Research, HDFC Securities.